US Pain Management Journal PPM Introduces Helixmith's Engensis

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 26th that the famous American pain treatment journal PPM (Practical Pain Management) introduced Helixmith's gene therapy drug ‘Engensis (VM202)’ as an emerging pain treatment.

PPM is a U.S. commercial magazine subscribed to by stakeholders in the pain management field, including hospitals, doctors, pharmaceutical companies, and pain marketing and sales companies.

Based on the results of the Phase 3 clinical trials (3-1, 3-1b) for diabetic peripheral neuropathy (DPN) announced by Helixmith this year, PPM recently introduced the excellent analgesic effect of Engensis (VM202), its long-lasting efficacy, and its superior pain relief effect in DPN patients not taking gabapentin-class drugs. In particular, citing the interpretation of a paper that although DNA drugs and HGF (hepatocyte growth factor) expression almost disappear two weeks after injection, the drug effect lasts for more than eight months thereafter, indicating the possibility of nerve regeneration, it highlighted the potential of regenerative medicine.

This report by the pain treatment specialty journal is interpreted as suggesting that the commercialization of Engensis (VM202) is approaching. In fact, the company is reorganizing its personnel and organization to accelerate the successful completion of the DPN Phase 3 clinical trial (3-2) and subsequent technology transfer and marketing authorization preparations.

‘Engensis (VM202)’ is a plasmid DNA gene therapy drug that expresses the HGF protein. It targets the root cause of neuropathy not by simple pain management but through angiogenesis and nerve regeneration effects. The U.S. FDA designated Engensis (VM202) as an Orphan Drug and Fast Track for the treatment of amyotrophic lateral sclerosis (ALS) in 2016, and as a Regenerative Medicine Advanced Therapy (RMAT) for the treatment of diabetic peripheral neuropathy (DPN) in 2018.

This content was produced with the assistance of AI translation services.